Loading stock data…
Niagen Bioscience, Inc. (NAGE)
$3.10-0.07 (-2.21%)
Market ClosedLast close Sep 8
Niagen Bioscience, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Niagen Bioscience, Inc. in the Consumer Defensive sector is trading at $3.10 with a market capitalization of $245M. Wall Street consensus targets $12.08 (6 analysts), implying a +289.8% move over the next 12 months. The stock is currently near its 52-week low of $2.87, remaining 33.5% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +289.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $29.79M↓ | $31.47M↓ | $33.84M↓ | $33.99M↑ | $31.12M |
| Gross Profit | $19.31M↓ | $19.98M↓ | $21.70M↓ | $21.93M↑ | $20.23M |
| Operating Income | $700,000↓ | $1.58M↓ | $2.10M↓ | $4.24M↑ | $3.19M |
| Net Income | $963,000↓ | $6.32M↑ | $4.13M↓ | $4.58M↑ | $3.61M |
Peer Comparison
Fundamentals
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that con...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$245.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.32
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.38%
Volume
Today's trading volume
531,399
Recent News
Does Niagen Bioscience's (NAGE) Walmart NAD+ Push Redefine Its Healthy‑Aging Brand Narrative?
In early August 2026, Niagen Bioscience Inc. reported slightly lower quarterly sales and net income year on year, while also expanding access to its Tru Niagen® healthy‑aging NAD+ supplement via Walmart.com, initially offering 300 mg bottles in 30‑ and 90‑count formats. A new peer‑reviewed analysis in Aging Cell linked Niagen’s nicotinamide riboside supplementation to reduced muscle epigenetic age acceleration, adding scientific depth to its healthy‑aging positioning just as distribution...
Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value
Niagen Bioscience (NAGE) is back in focus after a new peer reviewed study reported that its Niagen nicotinamide riboside supplementation was associated with reduced muscle epigenetic age acceleration compared with exercise based protocols. See our latest analysis for Niagen Bioscience. The recent clinical findings arrive after a difficult stretch for Niagen Bioscience’s stock. The 1 day share price return has fallen 14.7% and the year to date share price return has declined 52.64%. However,...
Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ...
Niagen Bioscience Inc (NAGE) reports strong TrueNiagen sales growth, China cross-border revenue exceeding full-year 2025 totals, and advances in pharmaceutical pipeline with promising PRV potential.
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -0.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Niagen Bioscience Stock Options
Investors need to pay close attention to NAGE stock based on the movements in the options market lately.